In conclusion, our current study suggests an accumulation of immunosuppressive Tregs in tumor microenvironment of myeloma patients by an overexpression of FOXP3 and CTLA4. Even in a still controversial scenario, we believe that this finding could bring new insights about possible biomarkers and therapeutic targets for MM. The gene discussed is FOXP3; the disease is neoplasm.